login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ACUMEN PHARMACEUTICALS INC (ABOS) Stock News
NASDAQ:ABOS -
US00509G2093
-
Common Stock
1.39
USD
-0.07 (-4.79%)
Last: 8/27/2025, 8:00:00 PM
1.36
USD
-0.03 (-2.16%)
After Hours:
8/27/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ABOS Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
a day ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
16 days ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
16 days ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
16 days ago - By: Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
4 months ago - By: Benzinga
A Preview Of Acumen Pharmaceuticals's Earnings
22 days ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
22 days ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
a month ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
a month ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
a month ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
a month ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
2 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
2 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
4 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
4 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
4 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
4 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
4 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
4 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
5 months ago - By: Climb Bio, Inc.
- Mentions:
CLYM
LENZ
SLDB
VERV
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
5 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
6 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
6 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
6 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
6 months ago - By: Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Please enable JavaScript to continue using this application.